Gilead Sciences Announces 10 Percent Increase in First Quarter 2017 Dividend
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- US stock futures dip as oil breaches $100 mark for the first time since mid-year
- Oil nears $100 as fresh Middle East strikes raise supply risks
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Gild Sciences (GILD) PT Drops to $75 at BMO on Bad Guidance
February 9, 2017 6:41 AM ESTBMO Capital Markets analyst M. Ian Somaiya maintains Market Perform rating, but drops price target on Gild Sciences (NASDAQ: GILD) to $75 (from $88), as the company delivered guidance well below consensus, forcing the Street to cut estimates.
Somaiya comments, "We are maintaining our Market... More
Gilead Sciences (GILD): 'Acquisition Wanted! - Please Apply Within'
February 8, 2017 11:09 AM ESTFollowing its 'kitchen sink' HCV guidance and subsequent 9% sell-off, the urgency for Gilead Sciences (NASDAQ: GILD) to make an acquisition continues to intensify. On the call, the company essentially admitted that it cannot grow over the next few years without a... More
Gilead Sciences (GILD) Pressured on Market Open, Shares Down 10%
February 8, 2017 9:40 AM ESTGilead Sciences (NASDAQ: GILD) Pressured on Market Open, Shares Down 10%
... MoreNeedham & Company Remains Sidelined on Gilead Sciences (GILD) Following 4Q
February 8, 2017 6:57 AM ESTNeedham & Company reiterated a Hold rating on Gilead Sciences (NASDAQ: GILD) following the company's 4Q earnings report.
Analyst Alan Carr commented, "Gilead reported 4Q16 financial results yesterday. Total 4Q16 revenue of $7.32B exceeded our $6.86B and consensus $7.14B estimates, driven by... More
Gilead (GILD) PT Drops to $87 at Baird on 2017 Guidance
February 8, 2017 6:19 AM ESTBaird analyst Brian Skorney maintains Outperform rating, but lowers price target on Gilead Sciences (NASDAQ: GILD) to $87 (from $100), as the company provided fiscal year revenue guidance well below consensus.
Skorney notes, 2017 guidance likely to bottom out stock. We believe investors were expecting... More
